TScan Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 22.56 million compared to USD 16.16 million a year ago. Basic loss per share from continuing operations was USD 0.93 compared to USD 0.67 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.41 USD | -3.33% | -6.35% | +44.25% |
05-13 | Janney Starts TScan Therapeutics With Buy Rating, $11 Price Target | MT |
05-13 | TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.25% | 481M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- TCRX Stock
- News TScan Therapeutics, Inc.
- TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023